Drug Discovery Services Market by Process (Target Selection, Validation, Lead Optimization), Type (Medicinal Chemistry, DMPK), Drug Type (Biologics, Small Molecules), Therapeutic (Oncology, Neurology), Company (Tier 1, 2, 3) - Global Forecast to 2025

創薬サービスの世界市場予測(〜2025):プロセス別(ターゲット選択、検証、リード最適化)、種類別(医薬品化学、DMPK)、薬剤種類別(生物、小分子)、治療別(腫瘍、神経)、企業別(ティア1、2、3)

◆タイトル:Drug Discovery Services Market by Process (Target Selection, Validation, Lead Optimization), Type (Medicinal Chemistry, DMPK), Drug Type (Biologics, Small Molecules), Therapeutic (Oncology, Neurology), Company (Tier 1, 2, 3) - Global Forecast to 2025
◆商品コード:PH 5682
◆調査・発行会社:MarketsandMarkets
◆発行日:2020年9月15日
◆ページ数:233
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥519,750見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥698,250見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥855,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

Marketsandmarkets社は創薬サービスの世界市場が2020年111億ドルから2025年214億ドルまで、年平均14.0%成長すると予測しています。本調査レポートでは、創薬サービスの世界市場を調査・分析することにより、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場動向、プロセス別(ターゲット選択、ターゲット検証、ヒットトゥリード識別、リード最適化)分析、種類別(薬用化学サービス、生物学サービス、DMPK)分析、薬剤種類別(小分子、生物学的薬物)分析、治療別(腫瘍、神経、感染症・免疫系疾患、消化器系疾患、心血管疾患)分析、企業別(ティア1、2、3)分析、地域別分析、競争状況、企業概要、隣接関連市場など、今後の方向性を明らかに致します。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場動向
・創薬サービスの世界市場規模:プロセス別(ターゲット選択、ターゲット検証、ヒットトゥリード識別、リード最適化)
・創薬サービスの世界市場規模:種類別(薬用化学サービス、生物学サービス、DMPK)
・創薬サービスの世界市場規模:薬剤種類別(小分子、生物学的薬物)
・創薬サービスの世界市場規模:治療別(腫瘍、神経、感染症・免疫系疾患、消化器系疾患、心血管疾患)
・創薬サービスの世界市場規模:企業別(ティア1、2、3)
・創薬サービスの世界市場規模:地域別
・競争状況
・企業概要
・隣接関連市場

“Increasing R&D spending and initiatives for rare disease and orphan drugs research are set to drive the drug discovery services market.’’
The drug discovery services market is projected to reach USD 21.4 billion by 2025 from USD 11.1 billion in 2020, at a CAGR of 14.0% during the forecast period. The major factors driving the growth of this market are the growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increasing demand for outsourcing analytical testing and clinical trial services, initiatives for research on rare diseases and orphan drugs, and focus on drug discovery. However, the high cost of drug discovery and development and stringent regulations governing drug discovery and animal usage in testing may restrict the growth of this market to a certain extent.

“By process, the Hit-to-Lead process accounted for the fastest-growing segment of the drug discovery service market.”
Hit-to-lead identification process is anticipated to be the fastest-growing segment due to the high outsourcing of these services to CROs by the pharmaceutical companies and the emerging advanced technologies for high-throughput screening (HTS) and H2L as well as reductions in development time.

“By type, the Medicinal Chemistry segment accounted for the largest share of the drug discovery service market.”
Based on type, the drug discovery services market is segmented into medicinal chemistry services, biology services, and drug metabolism and pharmacokinetics (DMPK). The medicinal chemistry services segment is estimated to account for the largest share of the drug discovery services market due to the widespread application of medicinal chemistry in various phases of preclinical drug discovery to deliver robust candidates.

“Oncology segment expected to grow at the fastest growth rate during the forecast period.”
Based on the therapeutic area, the drug discovery services market is segmented into oncology, cardiovascular diseases, neurology, infectious and immune system diseases, digestive system diseases, and other therapeutic areas. Of all these therapeutic segments, oncology will grow at the fastest CAGR in the drug discovery services market during forecast period.. The high growth of the oncology segment can be attributed to factors such as the increasing number of patients who have cancer, the subsequent increase in the demand for cancer therapies and the growing R&D expenditure by pharmaceutical companies in this therapeutic area.

“Asia Pacific: The fastest-growing region in the drug discovery services market.”
The Asia Pacific market is projected to grow at the highest CAGR during the forecast period, Several global pharmaceutical firms have entered the APAC market to tap the significant growth opportunities in emerging Asian countries and lower their production costs by shifting their manufacturing and drug discovery R&D operations to the region. As a result, the Asia Pacific region has become a major destination for drug discovery and development. A large number of qualified researchers and low-cost operations in APAC countries, such as India and China, are some of the major factors supporting this trend.

“North America: The largest share of the drug discovery servics market.”
North America, which includes the US and Canada, accounted for the largest share of the drug discovery services market. The large share of this region can primarily be attributed to the presence of well-established CROs; rising R&D expenditure by pharmaceutical & biopharmaceutical companies and the availability of latest techniques, instruments, and facilities for drug discovery research are driving the growth of this region.

Breakdown of primaries
The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:

• By Company–Tier 1- 40%, Tier 2- 30%, Tier 3- 30%
• By Designation— Executives- 25%, CXOs- 20%, Managers – 55%
• By Region— North America – 50%, Europe – 20%, APAC – 20%, RoW- 10%
The drug discovery services market is dominated by a few globally established players such as Thermo Fisher Scientific, Inc. (US), Albany Molecular Research, Inc. (US), Charles River Laboratories International, Inc. (US), Evotec SE (Germany), Domainex (UK), GenScript Biotech Corporation (China), Laboratory Corporation of America Holdings (US), WuXi AppTec (China), Pharmaceutical Product Development, LLC (US), Jubilant Biosys Ltd. (India), Eurofins Scientific SE (Luxembourg), Piramal Enterprises Ltd. (India), and Selvita S.A. (Poland).

Research Coverage:
The report segments the drug discovery services market based on region (North America, Asia Pacific, Europe, and RoW), process (target selection, target validation,hit-to-lead identification,lead optimization and candidate validation), type (medicinal chemistry, biology services, Drug Metabolism and Pharmacokinetics (DMPK)), and drug type (small molecules and biologics),Therapeutic Area ( Oncology, Neurology, infectious and Immune System Diseases, Diagestive System Disease, Cardiovascular Disease and others), Company type (Tier 1, tier 2, Tier3 pharmaceutical companies).The report also provides a comprehensive review of market drivers, challenges, and opportunities in the drug discovery services market.

Key Benefits of Buying the Report:
The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the ISH market and provides them information on key market drivers, challenges, and opportunities.

【レポートの目次】



★調査レポート[創薬サービスの世界市場予測(〜2025):プロセス別(ターゲット選択、検証、リード最適化)、種類別(医薬品化学、DMPK)、薬剤種類別(生物、小分子)、治療別(腫瘍、神経)、企業別(ティア1、2、3)] ( Drug Discovery Services Market by Process (Target Selection, Validation, Lead Optimization), Type (Medicinal Chemistry, DMPK), Drug Type (Biologics, Small Molecules), Therapeutic (Oncology, Neurology), Company (Tier 1, 2, 3) - Global Forecast to 2025 / PH 5682) 販売に関する免責事項
[創薬サービスの世界市場予測(〜2025):プロセス別(ターゲット選択、検証、リード最適化)、種類別(医薬品化学、DMPK)、薬剤種類別(生物、小分子)、治療別(腫瘍、神経)、企業別(ティア1、2、3)] ( Drug Discovery Services Market by Process (Target Selection, Validation, Lead Optimization), Type (Medicinal Chemistry, DMPK), Drug Type (Biologics, Small Molecules), Therapeutic (Oncology, Neurology), Company (Tier 1, 2, 3) - Global Forecast to 2025 / PH 5682) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆